Article
Clinical Neurology
Sung Hyun Kim, Hyemi Lee, Dong Wook Kim
Summary: The study investigated the seizure improvement in patients with drug-resistant epilepsy related to AED non-adherence after switching to once-daily dosing regimens. Results showed that successful switch was associated with patients without MRI abnormality and those switched to extended-release formulations or different AEDs with longer half-lives.
ACTA NEUROLOGICA SCANDINAVICA
(2021)
Article
Allergy
Heather De Keyser, Vy Vuong, Leanne Kaye, William C. Anderson, Stanley Szefler, David A. Stempel
Summary: This study assessed adherence differences in patients with asthma and COPD using once- or twice-daily doses of controller inhalers. The results showed that patients using once-daily doses had higher adherence compared to those using twice-daily doses. This finding was consistent across different age groups, except for adolescents with asthma. This study is important for understanding the impact of medication adherence on disease management.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE
(2023)
Article
Endocrinology & Metabolism
Ildiko Lingvay, John B. Buse, Edward Franek, Melissa V. Hansen, Mette M. Koefoed, Chantal Mathieu, Jeremy Pettus, Karolina Stachlewska, Julio Rosenstock
Summary: The study investigated the efficacy and safety of a novel once-weekly basal insulin analog, insulin icodec, using different titration algorithms. The results showed that icodec was efficacious and well tolerated across all three titration algorithms, with titration algorithm B demonstrating the best balance between glycemic control and risk of hypoglycemia.
Article
Multidisciplinary Sciences
Vivek Sood, Kajal Kamboj, Prateek Bhatia, Vishal Sharma, Monica Kundu, Arpita Ghosh, Sanjay Kumar Singh, Thakur Sen, Prabhjot Kaur, Raja Ramachandran, Manish Rathi, Harbir Singh Kohli, Krishan Lal Gupta, Samir Malhotra, Ashok Kumar Yadav, Vivek Kumar, Vivekanand Jha
Summary: This study investigated the effects of two dosing regimens of oral iron on iron status and hematological parameters in CKD patients. The results showed no significant difference in TSAT changes between the groups, but the OD group had a smaller increase in serum ferritin and an increase in MCHC compared to the BD group.
SCIENTIFIC REPORTS
(2023)
Article
Endocrinology & Metabolism
Harpreet S. Bajaj, Richard M. Bergenstal, Andreas Christoffersen, Melanie J. Davies, Amoolya Gowda, Joakim Isendahl, Ildiko Lingvay, Peter A. Senior, Robert J. Silver, Roberto Trevisan, Julio Rosenstock
Summary: The study demonstrated that switching from daily basal insulin to once-weekly icodec was well tolerated and provided effective glycemic control. The use of a loading dose when switching to once-weekly icodec significantly increased the percent time in range during weeks 15 and 16 compared to once-daily IGlar U100, without increasing the risk of hypoglycemia.
Article
Pharmacology & Pharmacy
Kohei Kitagawa, Ryuhei So, Nobuyuki Nomura, Masaru Tsukahara, Fuminari Misawa, Masafumi Kodama, Hiroyuki Uchida, Robert Bies, Thomas Straubinger, Christopher Banker, Yuya Mizuno, Masaru Mimura, Hiroyoshi Takeuchi
Summary: This study compared the actual plasma concentrations of clozapine between once-daily and divided dosing regimens, and examined their relationships with psychiatric symptoms and adverse effects. The results showed no significant differences in actual plasma concentrations or psychiatric symptoms between the two dosing strategies, suggesting that once-daily dosing of clozapine may be feasible and clinically useful.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
(2022)
Article
Multidisciplinary Sciences
Hui-Jeong Hwang, Il Suk Sohn, Eun-Sun Jin, Yoon-Jong Bae
Summary: This study found that twice-daily dosing of non-vitamin K antagonist oral anticoagulants (NOACs) may lead to reduced drug adherence and worsen clinical outcomes in patients with atrial fibrillation (AF). The adherence to each NOAC and the subsequent clinical outcomes were compared between different dosing regimens. The results showed that adherence was high and similar between once- and twice-daily dosing regimens, but patients with low adherence had poorer clinical outcomes regardless of the dosing frequency.
Review
Hematology
S. Mainbourg, M. Cucherat, S. Provencher, L. Bertoletti, P. Nony, F. Gueyffier, P. Mismetti, C. Grange, I. Durieu, R. Kilo, S. Laporte, G. Grenet, J. -C. Lega
Summary: The study indicates that there is no significant difference in terms of efficacy and safety between the once daily (QD) and twice daily (BID) dosing regimens of direct oral anticoagulants in major orthopedic surgery, non-valvular atrial fibrillation, venous thromboembolism, and acute coronary syndrome. No heterogeneity was found in the results for major thrombotic events and major bleeding.
THROMBOSIS RESEARCH
(2021)
Article
Infectious Diseases
Romain Palich, Clotilde Allavena, Gilles Peytavin, Cathia Soulie, Roland Tubiana, Laurence Weiss, Ana Montoya Ferrer, Claudine Duvivier, Olivier Bouchaud, Julie Bottero, Aurore Durand, Minh-Patrick Le, Anne-Genevieve Marcelin, Yasmine Dudoit, Lambert Assoumou, Christine Katlama
Summary: The study aimed to evaluate the efficacy of switching patients from a twice-daily to a once-daily regimen of etravirine/raltegravir in maintaining viral suppression. The results showed a low rate of virological failure and a high treatment success rate at 48 weeks post-switch.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
(2021)
Article
Biochemistry & Molecular Biology
Max M. Maurer, Marius Ibach, Julius Plewe, Axel Winter, Paul Ritschl, Brigitta Globke, Robert oellinger, Georg Lurje, Wenzel Schoening, Johann Pratschke, Dennis Eurich
Summary: The objective of this study was to investigate the adherence, efficacy, and safety after converting stable liver transplant patients from IR-Tac to LCP-Tac. The results showed that LCP-Tac improved adherence and was safe for use in liver transplant patients.
Article
Gastroenterology & Hepatology
Junwei Su, Stephanie Shiau, Stephen M. Arpadi, Renate Strehlau, Megan Burke, Faeezah Patel, Louise Kuhn, Ashraf Coovadia, Michael T. Yin
Summary: The study found that South African CHIV receiving ART had lower total body and regional fat distribution compared to healthy controls. In girls with HIV, switching from LPV/r to EFV may attenuate fat mass loss.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION
(2021)
Article
Medicine, General & Internal
Harpreet S. Bajaj, Jens Aberle, Melanie Davies, Anders Meller Donatsky, Marie Frederiksen, Dilek G. Yavuz, Amoolya Gowda, Ildiko Lingvay, Bruce Bode
Summary: This study compared the effectiveness and safety of icodec titrated with a dosing guide app to once-daily basal insulin analogues in treating patients with type 2 diabetes. The results showed that icodec with app was more effective in reducing HbA1c levels, improving treatment satisfaction and compliance, with similar rates of hypoglycemia compared to OD analogues.
ANNALS OF INTERNAL MEDICINE
(2023)
Article
Pharmacology & Pharmacy
Thanompong Sathienluckana, Thaksin Jansing, Supakan Srisuriyakamon, Aunchalee Thonkhunthod, Parsiri Sangsuwanto, Pholphat Losatiankij, Suttha Supanya
Summary: This study compared the efficacy and safety of once-daily and divided dosing of clozapine and found no significant differences in all-cause discontinuation and adverse events between the two administration methods.
ANNALS OF PHARMACOTHERAPY
(2023)
Article
Multidisciplinary Sciences
Musa Otieno Ngayo, Margaret Oluka, Wallace Dimbuson Bulimo, Faith Apolot Okalebo
Summary: HIV stigma, lack of disclosure, and inadequate social support are still prevalent among HIV-infected patients in Kenya. These social-psychological factors are associated with varying plasma concentrations of nevirapine (NVP) and efavirenz (EFV) in HIV patients, potentially impacting drug efficacy.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Ying C. Ou, Zhiyu Tang, William Novotny, Aileen Cohen, Kun Wang, Lucy Liu, Yuying Gao, Srikumar Sahasranaman
Summary: This report summarizes the evidence supporting the recommendation of a 320-mg total daily dose for zanubrutinib in patients with mantle cell lymphoma, with data from phase 2 and phase 1/2 studies showing similar response rates with 160-mg BID or 320-mg QD regimens. Population pharmacokinetics and exposure-response analyses bridged the two regimens, demonstrating similar plasma exposure and BTK inhibition. The totality of data supports the 320-mg total daily dose for the approved indication.
LEUKEMIA & LYMPHOMA
(2021)